Granted Patent
B2
US 12,653,887 · App. 17/609,705 · Granted Jun 16, 2026
T cell manufacturing compositions and methods
Inventors:
Marit M. van Buuren (Belmont, MA); Divya Reddy Lenkala (Watertown, MA); Jessica Kohler (Boston, MA); Flavian Duvalle Brown (Boston, MA); Christina Murphy Kuksin (Cambridge, MA); Joost Huibert van den Berg (Amsterdam, NL); Renate de Boer (Diemen, NL); Noor Bakker (Haarlem, NL); Ton Schumacher (Aloemehomal, NL); John Haanen (Amsterdam, NL)
A61K40/13A61K40/11A61K40/4201A61K40/4271C12N5/0081C12N5/0636C12N5/0638A61K2239/31A61K2239/38A61K2239/57A61K2239/59
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
Claims (50)
1 . A method of treating a cancer in a human subject in need thereof, comprising:
(a) depleting CD14+ cells and/or CD25+ cells from a washed and/or cryopreserved peripheral blood mononuclear cell (PBMC) sample from the human subject comprising antigen presenting cells (APCs) and T cells, thereby forming a CD14 and/or CD25 depleted PBMCs comprising a first population of APCs and T cells;
(b) incubating the first population of APCs and T cells from step (a) for a first time period in the presence of:
(i) FMS-like tyrosine kinase 3 receptor ligand (FLT3L), and
(ii) (A) a polypeptide comprising at least two different tumor antigen epitope sequences expressed by cancer cells of a human subject with cancer, or (B) a polynucleotide encoding the polypeptide comprising the at least two different tumor antigen epitope sequences expressed by cancer cells of the human subject with cancer, and wherein the at least two different tumor antigen epitope sequences are not expressed in non-cancer cells of the human subject;
thereby forming a population of cells comprising stimulated T cells;
(c) expanding the stimulated T cells from step (b), thereby forming an expanded population of cells comprising tumor antigen-specific T cells,
wherein the tumor antigen-specific T cells comprise T cells that are specific to a complex comprising (i) a tumor antigen epitope sequence of the at least two different tumor antigen epitope sequences from step (b)(ii), and (ii) an MHC protein expressed by the cancer cells or APCs of the human subject; and
(d) administering the expanded population of cells from (c) to the human subject, wherein the human subject:
(i) has unresectable melanoma,
(ii) has previously received a PD-1 inhibitor or PD-L1 inhibitor and a CTLA-4 inhibitor containing regimen and has disease progression, or
(iii) has received or is currently receiving a PD-1 inhibitor or PD-L1 inhibitor for at least 3 months and has stable disease or asymptomatic progressive disease.
2 . The method of claim 1 , wherein incubating in (b) comprises introducing an mRNA encoding the polypeptide into the APCs of the first population of APCs and T cells from step (a), wherein introducing comprises electroporating or nucleofecting, and wherein the electroporating or nucleofecting is carried out without separating the T cells from the APCs of the first population of APCs and T cells from step (a).
3 . The method of claim 2 , wherein the mRNA comprises a 5′ CAP and a 3′ polyA tail.
4 . The method of claim 3 , wherein the 5′ CAP is CAP-1.
5 . The method of claim 4 , wherein the 5′ CAP is operably linked to a tumor antigen epitope sequence of the at least two different tumor antigen epitope sequences via a linker sequence.
6 . The method of claim 3 , wherein the polyA tail is from 120 to 135 nucleotides in length.
7 . The method of claim 1 , wherein the at least two different tumor antigen epitope sequences are expressed as a single polypeptide chain, and wherein a first tumor antigen epitope sequence of the at least two different tumor antigen epitope sequences is connected to a second tumor antigen epitope sequence of the at least two different tumor antigen epitope sequences via a linker sequence.
8 . The method of claim 1 , wherein the polypeptide comprises at least 4 different tumor antigen epitope sequences expressed by cancer cells of a human subject with cancer.
9 . The method of claim 1 , wherein:
(i) percentage of CD3+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 40% of total cell population;
(ii) percentage of CD107a+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 10% of the tumor antigen-specific T cell population;
(iii) percentage of TNFα+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 5% of the tumor antigen-specific T cell population;
(iv) percentage of IFNγ+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 15% of the tumor antigen-specific T cell population;
(v) percentage of TNFα+ and IFNγ+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 2% of the tumor antigen-specific T cell population;
(vi) percentage of TNFα+ and CD107a+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 0.5% of the tumor antigen-specific T cell population;
(vii) percentage of IFNγ+ and CD107a+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 5% of the tumor antigen-specific T cell population; and/or
(viii) percentage of TNFα+ and IFNγ+ and CD107a+ cells in the expanded population of cells comprising tumor antigen-specific T cells is at least 0.1% of the tumor antigen-specific T cell population.
10 . The method of claim 1 , wherein:
(i) percentage of CD4+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are naive T cells (CD62L+ and CD45RA+) is at most 15%;
(ii) percentage of CD4+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are effector memory T cells (CD62L− and CD45RA−) is at least 60%;
(iii) percentage of CD4+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are effector T cells (CD62L− and CD45RA+) is at most 5%; and/or
(iv) percentage of CD4+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are central memory T cells (CD62L+ and CD45RA−) is at least 10%.
11 . The method of claim 1 , wherein:
(i) percentage of CD8+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are naive T cells (CD62L+ and CD45RA+) is at most 25%;
(ii) percentage of CD8+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are effector memory T cells (CD62L− and CD45RA−) is at least 60%;
(iii) percentage of CD8+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are effector T cells (CD62L− and CD45RA+) is at most 10%; and/or
(iv) percentage of CD8+ T cells in the expanded population of cells comprising tumor antigen-specific T cells that are central memory T cells (CD62L+ and CD45RA−) is at least 15%.
12 . The method of claim 1 , wherein the expanded population of cells comprising tumor antigen-specific T cells produce cytokines and cause degranulation upon recognition of target cells.
13 . The method of claim 1 , wherein the human subject
(i) is refractory to an anti-checkpoint inhibitor therapy;
(ii) is age 18 to 75 years old; and/or
(iii) has a mutation in a BRAF gene and has previously received a B-raf inhibitor or a B-raf/MEK combination therapy.
14 . The method of claim 1 , wherein depleting comprises depleting CD14+ cells and CD25+ cells from a peripheral blood mononuclear cell (PBMC) sample from a human subject that has not been subject to a step of monocyte maturation into mature dendritic cells (DCs).
15 . The method of claim 1 , wherein depleting further comprises depleting CD11b+ cells from the peripheral blood mononuclear cell (PBMC) sample from the human subject that has not been subject to a step of monocyte maturation into mature dendritic cells (DCs).
16 . The method of claim 1 , wherein
(i) at least 0.1% of the CD8+ T cells in the expanded population of cells comprising tumor antigen specific T cells are CD8+ tumor antigen-specific T cells derived from naïve CD8+ T cells; and/or
(ii) at least 0.1% of the CD4+ T cells in the expanded population of cells comprising tumor antigen specific T cells are CD4+ tumor antigen-specific T cells derived from naïve CD4+ T cells.
17 . The method of claim 1 , wherein the expanded population of cells from step (c) administered to the human subject comprises from 1×10 8 to 1×10 11 total cells.
18 . The method of claim 1 , wherein depleting comprises contacting the washed and/or cryopreserved peripheral blood mononuclear cell (PBMC) sample from the human subject with anti-CD14 antibody and/or anti-CD25 antibody respectively.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 17, 2025
From: HAANEN, JOHN
To: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Reel/Frame 072922/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 17, 2025
From: VAN DEN BERG, JOOST HUIBERT; DEBOER, RENATE; BAKKER, NOOR; SCHUMACHER, TON
To: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Reel/Frame 072922/0267 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 17, 2025
From: VAN BUUREN, MARIT M.; LENKALA, DIVYA REDDY; KOHLER, JESSICA; KUKSIN, CHRISTINA MURPHY; BROWN, FLAVIAN DUVALLE
To: BIONTECH US INC.
Reel/Frame 073606/0876 →
Continuity (2)
Provisional Application
62845251
· May 8, 2019
References Cited (400)
US 5391377A
· Barnwell
· 1995
[cited by applicant]
US 5849589A
· Tedder et al.
· 1998
[cited by applicant]
US 5994126A
· Steinman et al.
· 1999
[cited by applicant]
US 6406705B1
· Davis et al.
· 2002
[cited by applicant]
US 7276478B2
· Sivakumar et al.
· 2007
[cited by applicant]
US 9115402B2
· Hacohen et al.
· 2015
[cited by applicant]
US 9476055B2
· Sahin et al.
· 2016
[cited by applicant]
US 9809797B2
· Yee et al.
· 2017
[cited by applicant]
US 20090285843A1
· Simard et al.
· 2009
[cited by applicant]
US 20110274723A1
· Bot et al.
· 2011
[cited by applicant]
US 20150104441A1
· Olweus et al.
· 2015
[cited by applicant]
US 20190119639A1
· Oelke et al.
· 2019
[cited by applicant]
US 20220282217A1
· Ang et al.
· 2022
[cited by applicant]
US 20230374455A1
· Juneja et al.
· 2023
[cited by applicant]
US 20230398218A1
· Juneja
· 2023
[cited by applicant]
CN 103923880A
· 2014
[cited by applicant]
CN 109476722A
· 2019
[cited by applicant]
EP 2749639A1
· 2014
[cited by applicant]
EP 3023788A1
· 2016
[cited by applicant]
EP 3335725A1
· 2018
[cited by applicant]
EP 3699266A1
· 2020
[cited by applicant]
RU 2447900C2
· 2012
[cited by applicant]
RU 2793344C2
· 2023
[cited by applicant]
TW 201738378A
· 2017
[cited by applicant]
WO WO9403205A1
· 1994
[cited by applicant]
WO WO9420127A1
· 1994
[cited by applicant]
WO WO2006015497A1
· 2006
[cited by applicant]
WO WO2006110582A1
· 2006
[cited by applicant]
WO WO2007036366A2
· 2007
[cited by applicant]
WO WO2009045308A2
· 2009
[cited by applicant]
WO WO2009106073A2
· 2009
[cited by applicant]
WO WO2011143656A2
· 2011
[cited by applicant]
WO WO2012159643A1
· 2012
[cited by applicant]
WO WO2013118899A1
· 2013
[cited by applicant]
WO WO2015095811A2
· 2015
[cited by applicant]
WO WO2015164675A1
· 2015
[cited by applicant]
WO WO2016201394A1
· 2016
[cited by applicant]
WO WO2017015427A1
· 2017
[cited by applicant]
WO WO2017026389A1
· 2017
[cited by examiner]
WO WO2017044661A1
· 2017
[cited by applicant]
WO WO2017044859A1
· 2017
[cited by applicant]
WO WO2017173321A1
· 2017
[cited by applicant]
WO WO2017177337A1
· 2017
[cited by applicant]
WO WO2017184590A1
· 2017
[cited by applicant]
WO WO2018005556A1
· 2018
[cited by applicant]
WO WO2018026914A1
· 2018
[cited by applicant]
WO WO2018148671A1
· 2018
[cited by applicant]
WO WO2019094642A1
· 2019
[cited by applicant]
WO WO2020047449A2
· 2020
[cited by applicant]
WO WO2020132586A1
· 2020
[cited by applicant]
WO WO2020205778A1
· 2020
[cited by applicant]
WO WO2020227546A1
· 2020
[cited by applicant]
WO WO2022036137A1
· 2022
[cited by applicant]
WO WO2023064930A1
· 2023
[cited by applicant]
WO WO2024124222A1
· 2024
[cited by applicant]
Shin, H., Park, S.-J., Yim, Y., Kim, J., Choi, C., Won, C. and Min, D.-H. (2018), Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles. Adv. Therap., 1: 1800065. (Year: 2018).
[cited by examiner]
Sheng, Kuo-Ching, Day, Stephanie, Wright, Mark D., Stojanovska, Lily, Apostolopoulos, Vasso, Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR Stimulation, Journal of Drug Deliv…
[cited by examiner]
Pletinckx K, Lutz MB. Dendritic cells generated with Flt3L and exposed to apoptotic cells lack induction of T cell anergy and Foxp3
[cited by examiner]
Nezafat N, Ghasemi Y, Javadi G, Khoshnoud MJ, Omidinia E. A novel multi-epitope peptide vaccine against cancer: an in silico approach. J Theor Biol. May 21, 2014;349:121-34. (Year: 2014).
[cited by examiner]
Peng W, Lizée G, Hwu P. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology. Feb. 1, 2013;2(2):e22691. (Year: 2013).
[cited by examiner]
Verdegaal, E.M.E., Visser, M., Ramwadhdoebé, T.H. et al. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose int…
[cited by examiner]
Varga et al. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood. Jan. 15, 2007;109(2):661-9. (Year: 2007).
[cited by examiner]
Gjertsen et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. May 1…
[cited by examiner]
Lawrence, M., Stojanov, P., Mermel, C. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014). (Year: 2014).
[cited by examiner]
“Ali, et al., “Induction of neoantigen-reactive T cells from healthy donors” , Nature Protocols (2019)”.
[cited by applicant]
Allison, “The Mode of Action of Immunological Adjuvants,” Dev Biol Stand, 92: 3-11 (1998).
[cited by applicant]
Bernhard et al., Generation of Immunostimulatory Dendritic Cells From Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood, Cancer Res. 55:1099-104 (1995).
[cited by applicant]
Bishop, MR, et al., High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft, Blood, vol. 83, No. 2, pp. 610-…
[cited by applicant]
Bollard, et al., “Sustained complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins” Journal of Clinical Oncology, vol. 32, No. 8 (…
[cited by applicant]
Busch et al., Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces, Int. Immunol. 2:443 (1990).
[cited by applicant]
“Carreno, et al., “IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity” J. Clin Invest (2013) 123(8):3383-3394, Vole 123, No. 8”.
[cited by applicant]
Ceppellini et al., Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells, Nature 339:392 (1989).
[cited by applicant]
Cerundolo et al., The binding affinity and dissociated rates of peptides for class I major histocompatibility complex molecules, Eur. Immunol., 21:2069-75 (1991).
[cited by applicant]
Christnick et al., Peptide binding to class 1MHC on living cells and quantitation of complexes required for CTL lysis, Nature 352:67 (1991).
[cited by applicant]
Del Guercio, M.F., et al., Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype, J. Immunol. 154:685-693 (1995).
[cited by applicant]
Dupuis, M., et al., Dendritic Cells Internalize Vaccine Adjuvant after Intramuscular Injection, Cell Immunol. 1998; 186(1):18-27.
[cited by applicant]
“Erdmann, et al., “Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy” Journal of Immunological Methods (463 (2018) 89-96”.
[cited by applicant]
Exam Report and Translation issued in Russian Patent Application No. 2021106561/10 on Dec. 29, 2021.
[cited by applicant]
Exam Report and Translation issued in Russian Patent Application No. 2021106561/10 on May 26, 2022.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 19849341.3 on Apr. 8, 2022.
[cited by applicant]
Fix. Oral controlled release technology for peptides: status and future prospects. Pharm Res. 13(12):1760-1764 (1996).
[cited by applicant]
Freudenthal, et al. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A. Oct. 1990;87(19):7698-702.
[cited by applicant]
“Fritsch, et al., “HLA-binding properties of tumor neoepitopes in humans”, Cancer Immunol Res (2014) p. 1-27”.
[cited by applicant]
Gabrilovich, et al., “IL-12 and Mutant P53 Peptide-Pulsed Dendritic Cells for the Specific Immunotherapy of Cancer,” J Immunother Emphasis Tumor Immunol, 19(6): 414-418 (1997).
[cited by applicant]
Gamvrellis, A. et al., Vaccines that facilitate antigen entry into dendritic cells, Immunol & Cell Biol. 2004; 82: 506-516.
[cited by applicant]
“Gattinoni, et al., “A human memory T-cell subset with stem cell-like properties” Nat Med; 17(10): 1290-1297 (2012)”.
[cited by applicant]
“Gilboa, Eli, “The Making of a Tumor Rejection Antigen” Immunity. vol. 11, p. 263-270 (1999)”.
[cited by applicant]
Gjertsen et al., Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autolog…
[cited by applicant]
Hammer, J. et al., Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning, J. Exp. Med. 180:2353 (1994).
[cited by applicant]
Hill et al., Conformational and structural characteristics of peptides binding to HLA-DR molecules, J. Immunol. 147:189 (1991).
[cited by applicant]
Hill et al., Exploration of requirements for peptide binding to HLA DRB10101 and DRBI*0401, J. Immunol. 152, 2890 (1994).
[cited by applicant]
International Search Report and Written Opinion dated Mar. 4, 2019, for PCT/US2018/59896.
[cited by applicant]
“International Search Report and Written Opinion for corresponding PCT Application No. PCT/US2019/046876 issued Jan. 21, 2020”.
[cited by applicant]
Khilko, Sergi N. et al., Direct Detection of Major Histocompatibility Complex Class I Binding to Antigenic Peptides Using Surface Plasmon Resonance, J. Biol. Chem. 268:15425 (1993).
[cited by applicant]
“Klebanoff, et al., “Sortying through subsets: Which T cell poulations mediate highly effective adoptive immunotherapy?”, J. Immunother. (2012) 35(9): p. 651-660”.
[cited by applicant]
“Koski, et al., “CD14+ Monocytes as Dendritic Cell Precursors: Diverse Maturation-Inducing Pathways Lead to Common Activation of NF-kB/RelB”, Critical Reviews in Immunology, 21:179-189 (2001)”.
[cited by applicant]
Krieg, Arthur M., Therapeutic potential of Toll-like receptor 9 activation, Nature Reviews, Drug Discovery, 5, Jun. 2006, 471-484).
[cited by applicant]
“Leen, et al., “Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation”, Blood (2009) vol.…
[cited by applicant]
Li et al., TCRβ repertoire of CD4+ and CD8+ T cells is distinct in richness, distribution, and CDR3 amino acid composition. J Leukoc Biol. Mar. 2016;99(3):505-13. doi: 10.1189/jlb.6A0215-071RR. Epub Sep. 22, 2015. PMID:…
[cited by applicant]
“Linnemann, et al., “High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma” Nature Medicine (2015) vol. 21, No. 1, p. 81-87”.
[cited by applicant]
“Lissina, et al., “Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand” J. Immunol (2016) 196:256-263”.
[cited by applicant]
Ljunggren et al., Empty MHC class I molecules come out in the cold, Nature 346:476 (1990).
[cited by applicant]
“Maraskovsky, et al., “In vivo generation of human dendritic cell subsets by Flt3 lignad” (2000) Blood, vol. 96, No. 3, pp. 878-884”.
[cited by applicant]
Markowicz, et al. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest. Mar. 1990;85(3):955-61.
[cited by applicant]
Mosca, Paul J. et al., Dendritic cell vaccines, Frontiers in Bioscience, (2007) 12:4050-4060).
[cited by applicant]
“Nair, et al., “Isolation and Generation of Human Dendritic Cells” Curr Protoc Immunol (2012)”.
[cited by applicant]
O'Doherty, et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med. Sep. 1, 1993;178(3):1067…
[cited by applicant]
Parker et al., The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC Class I heterotrimers and depends on which peptide is bound, J. Immunol. 149:1896 (1992).
[cited by applicant]
Reay, Phillip A. et al., (1992), pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule, EMBO J. 11:2829-39.
[cited by applicant]
Samanen et al. Chemical approaches to improve the oral bioavailability of peptidergic molecules. J. Pharm. Pharmacol. 48:119-135 (1996).
[cited by applicant]
Schumacher, Ton N.M., et al., (1990), Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro, Cell 62:563 (1990).
[cited by applicant]
Sette, et al., (1994) Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular bindings assays, Mol. Immunol. 31:813.
[cited by applicant]
Sidney, John et al., Measurement of MHC/Peptide Interactions by Gel Filtration Curr Prot Immunol, 31(1):18.3.1-18.3.19 (1999).
[cited by applicant]
Townsend, A., et al., Assembly of MCH Class I molecules analyzed in vitro, Cell 62:285, Jul. 27, 1990.
[cited by applicant]
“Stronen, et al., “Dendritic Cells Engineered to Express Defined Allo-HLA Peptide Complexes Induce Antigen-specific Cytotoxic T Cells Efficiently Killing Tumour Cells”, Scandinavian Journal of Immunology (2009) 69, pp. …
[cited by applicant]
“Van Buuren, et al., “High sensitivity of cancer exome-based CD8 T cell neo-antigen identification” Oncolmmunology 3, (2014)”.
[cited by applicant]
Wang et al. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res. Mar. 2016;4(3):204-14. doi: 10.1158/2326-6066.CIR-15-0188. Epub Dec. 23, 2015. PMID: 26701267; PMCID: PMC4775432.
[cited by applicant]
Young, et al. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med. Apr. 1, 1990;171(4):1315-32.
[cited by applicant]
Sakaguchi, et al., “Regulatory T Cells and Immune Tolerance” Cell 133, May 30, 2008, p. 775-787.
[cited by applicant]
Kurd, et al., “T cell selection in the thymus: a spatial and temporal perspective” Immunol Rev (2016): 271(1): p. 114-126.
[cited by applicant]
Andersen, et al., “Dissection of T-cell Antigen Specificity in Human Melanoma” Cancer Res; 72(7) Apr. 1, 2012, p. 1642-1650.
[cited by applicant]
Abdelhakim: The activation marker CD137 identifies a highly active subset of donor lymphocytes agaiast acute myeloid leukemia future. Biol. Blood Marrow Transplant. 25(3):290-442 (2019) Abstract.
[cited by applicant]
Al-Kadhimi, Zaid. et al. The Use of Clinical Grade Magnetic Beads to Deplete Immune Suppressive Elements from Autologous Peripheral Blood Hematopoietic Stem Cell Grafts Enhances T Cell Immune Responses. Blood 112(11):23…
[cited by applicant]
Boon, Thierry, et al., Human T Cell Responses Against Melanoma. Annual Review of Immunology 24:175-208 (2006).
[cited by applicant]
Borgers et al: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med 31:881-893 (2025).
[cited by applicant]
Borish, Larry. et al. Cytokines and chemokines. J Allergy Clin Immunol 111(2 Suppl):S460-475 (2003).
[cited by applicant]
Chae, Young Kwang. et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non- small cell lung cancer (NSCLC). J Im…
[cited by applicant]
Dengjel, Jorn, et al., Glycan Side Chains on Naturally Presented MHC Class IL Ligands. Journal of Mass Spectrometry 40(1):100-104 (2005).
[cited by applicant]
Dermer, Gerald B, et al., Another Anniversary for the War on Cancer. Biotechnology 12:320 (1994).
[cited by applicant]
Di Stasi, Antonio, et al., Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. The New England Journal of Medicine 365(18):1673-1683 (2011).
[cited by applicant]
Ding, Li, et al., Genome Remodelling in a Basal-like Breast Cancer Metastasis and Xenograft. Nature 464:999-1005 (2010).
[cited by applicant]
Ding, Li, et al., Somatic Mutations Affect Key Pathways in Lung Adenocarcinoma. Nature 455:1069-1075 (2008).
[cited by applicant]
Dong et al.: Flt-3 Ligand: A Potent Dendritic Cell Stimulator and Novel Antitumor. Cancer Biology & Therapy. 1(5):486-489 (2002).
[cited by applicant]
Efremova, et al.: Neoantigens Generated By Individual Mutations And Their Role in Cancer Immunitya nd Immunotherapy. Frontiers in Immunology (2017) vol. 8, pp. 1-8.
[cited by applicant]
Eisenhauer, E A. et al. New Response Evaluation Criteria In Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer 45(2):228-247 (2009).
[cited by applicant]
EP11781409.5 Extended European Search Report dated Apr. 16, 2014.
[cited by applicant]
EP15198284.0 Extended European Search Report dated Apr. 11, 2016.
[cited by applicant]
EP20801696.4 Extended European Search Report dated May 22, 2023.
[cited by applicant]
EP21856741.0 European Search Report dated Jul. 22, 2024.
[cited by applicant]
Erlich, Rachel L, et al., Next-Generation Sequencing for HLA Typing of Class I Loci. BMC Genomics 12(1):42, 39pages (2011).
[cited by applicant]
Hacohen, Nir, et al., Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. Cancer immunology research 1(1):11-15 (2013).
[cited by applicant]
Hadrup, Sine Reker. et al. Parallel Detection of Antigen-Specific T-CellResponses by Multidimensional Encoding of MHC Multimers. Nature Methods 6(7):520-526 (2009).
[cited by applicant]
Halabi, Susan. et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. Journal of Clinical Oncology 21(7):1232-1237 (2003).
[cited by applicant]
Hall, Neil. Advanced Sequencing Technologies and Their Wider Impact in Microbiology. Journal of Experimental Biology 210(9):1518-1525 (2007).
[cited by applicant]
Hamanishi, Junzo. et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 21(3):462-473 (2016).
[cited by applicant]
Han, Arnold, et al., Linking T-Cell Receptor Sequence to Functional Phenotype at the Single-Cell Level. Nature Biotechnology 32(7):684-692 (2014).
[cited by applicant]
Hanahan, Douglas, et al., Hallmarks of Cancer: The Next Generation. Cell 144(5): 646-674 (2011).
[cited by applicant]
Hansen, Kasper Daniel, et al. Increased Methylation Variation in Epigenetic Domains Across Cancer Types. Nature Genetics 43(8):768-775 (2011).
[cited by applicant]
Hanzelmann, Sonja, et al., GSVA: Gene Set Variation Analysis for Microarray and RNA-seq Data. BMC Bioinformatics, 14:7,15 Pages (2013).
[cited by applicant]
Harndahl, Mikkel, et al., Peptide-MHC Class I Stability is a Better Predictor than Peptide Affinity of CTL Immunogenicity. European Journal of Immunology 42(6):1405-1416 (2012).
[cited by applicant]
Harndahl, Mikkel et al. Real-time, High-Throughput Measurements of Peptide-MHC-I Dissociation Using a Scintillation Proximity Assay. Journal of Immunological Methods vol. 374, 1-2: pp. 5-12 (2011).
[cited by applicant]
Harris, R Alan, et al., Comparison of Sequencing-based Methods to Profile DNA Methylation and Identification of Monoallelic Epigenetic Modifications. Nature Biotechnology 28(10):1097-1105 (2010).
[cited by applicant]
Harris, Reuben S, et al., RNA Editing Enzyme APOBECI and some of its Homologs can Act as DNA Mutators. Molecular Cell 10(5):1247-1253 (2002).
[cited by applicant]
Hartley et al.: Pancreatic cancer, treatment options, and GI-4000. Human Vaccines & Immunotherapeutics 11(4):931-937 (2015).
[cited by applicant]
He et al., RAS gene mutations in Chinese leukaemia patients and members of a family with high incidence of leukaemia. Leuk Res. Nov.-Dec. 1996;20(11-12):901-3. doi: 10.1016/s0145-2126(96)00044-6. PMID: 9009246.
[cited by applicant]
Heemskerk, Bianca. et al. The Cancer Antigenome. EMBO Journal 32(2):194-203 (2013).
[cited by applicant]
Hel, Zdenek. et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. Journal of immunology 167(12):7180-7191 (2001).
[cited by applicant]
Herbeuval, Jean-Philippe, et al., HAART Reduces Death Ligand but not Death Receptors in Lymphoid Tissue of HIV-Infected Patients and Simian Immunodeficiency Virus-Infected Macaques. AIDS 23(1):35-40 (2009).
[cited by applicant]
Herbst, Roy S, et al., Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature 515(7528):563-567 (2014).
[cited by applicant]
Herman, J, et al., Differences in the Recognition by CTL of Peptides Presented by the HLA-B* 4402 and the HLA-B*4403 Molecules Which Differ by a Single Amino Acid. Tissue Antigens 53(2):111-121 (1999).
[cited by applicant]
Herman, S E M, et al., Ibrutinib-Induced Lymphocytosis in Patients With Chronic Lymphocytic Leukemia: Correlative Analyses From a Phase II Study. Leukemia 28(11):2188-2196 (2014).
[cited by applicant]
Hersey, Peter, et al., Phase I/II Study of Treatment with Dendritic cell Vaccines in Patient with Disseminated Melanoma. Cancer Immunol Immunother 53(2):125-134 (2004).
[cited by applicant]
Hickman, Heather, et al., Toward a Definition of Self: Proteomic Evaluation of the Class I Peptide Repertoire. Journal of Immunology 172(5):2944-2952 (2004).
[cited by applicant]
Hinrichs, Christian S, et al., Exploiting the Curative Potential of Adoptive T-cell Therapy for Cancer. Immunological Reviews 257(1):56-71 (2014).
[cited by applicant]
Hocker, Thomas, et al., Ultraviolet Radiation and Melanoma: A Systematic Review and Analysis of Reported Sequence Variants. Human mutation 28(6):578-588 (2007).
[cited by applicant]
Hodi, F Stephen, et al., Biologic Activity of Cytotoxic T Lymphocyte-Associated Antigen 4 Antibody Blockade in Previously Vaccinated Metastatic Melanoma and Ovarian Carcinoma Patients. Proceedings of the National Academ…
[cited by applicant]
Hodi, F Stephen, et al., Immunologic and Clinical Effects of Antibody Blockade of Cytotoxic T Lymphocyte-Associated Antigen 4 in Previously Vaccinated Cancer Patients. Proceedings of the National Academy of Sciences of …
[cited by applicant]
Hodi, F Stephen, et al., Improved Survival With Ipilimumab in Patients With Metastatic Melanoma. The New England Journal of Medicine 363(8):711-723 (2010).
[cited by applicant]
Hombrink, Pleun. et al. High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations. PLoS One 6(8): e22523, 1-11 (2011).
[cited by applicant]
Hombrink, Pleun, et al., Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach. Clinical Cancer Research 21(9):2177-218…
[cited by applicant]
Honigberg, Lee A, et al., The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-cell Activation and is Efficacious in Models of Autoimmune Disease and B-cell Malignancy. Proceedings of the National Academy of Sciences…
[cited by applicant]
Horig, Heidi. et al. Phase 1 Clinical Trial of a Recombinant Canarypoxvirus (ALVAC) Vaccine Expressing Human Carcinoembryonic Antigen and the B7.1 Co-stimulatory Molecule. Cancer Immunology Immunotherapy 49(9):504-514 (…
[cited by applicant]
Illumina, Immunotherapy, the Next Generation of Cancer Treatment, NGS-guided assessment of interactions between tumors and the immune system leads to new discoveries in immuno-oncology. 1-10 (2016).
[cited by applicant]
Inokuchi, Koiti, et al., DCC Protein Expression in Hematopoietic Cell Populations and Its Relation to Leukemogenesis. The Journal of Clinical Investigation 97(3):852-857 (1996).
[cited by applicant]
International Search Report and Written Opinion in corresponding PCT Application No. PCT/US2019/038019 dated Dec. 4, 2019.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2020/025796 on Jun. 23, 2020.
[cited by applicant]
Ishihama, Yasushi, et al., Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides Per Protein. Molecular & Cellular Proteomics …
[cited by applicant]
Izeradjene, Kamel, et al., Casein Kinase II (CK2) Enhances Death-inducing Signaling Complex (DISC) Activity in TRAIL-induced Apoptosis in Human Colon Carcinoma Cell Lines. Oncogene 24(12):2050-2058 (2005).
[cited by applicant]
Jaatinen, Taina, et al., Global Gene Expression Profile of Human Cord Blood-derived CD133+ Cells. Stem Cells 24(3):631-641 (2006).
[cited by applicant]
Jarmalavicius, Saulius, et al., High Immunogenicity of the Human Leukocyte Antigen Peptidomes of Melanoma Tumor Cells. The Journal of Biological Chemistry 287(40):33401-33411 (2012).
[cited by applicant]
Jayasinghe, Reyka G, et al., Systematic Analysis of Splice-site-creating Mutations in Cancer. Cell Reports 23(1):270-281 (2018).
[cited by applicant]
Jeffery, K J, et al., The Influence of HLA Class I Alleles and Heterozygosity on the Outcome of Human T Cell Lymphotropic Virus Type I Infection. Journal of Immunology 165(12):7278-7284 (2000).
[cited by applicant]
Jema, Ahmedin, et al., Cancer statistics, 2007. CA Cancer Journal for Clinicians 57(1):43-66 (2007).
[cited by applicant]
Jennewein, Carla, et al., Sumoylation of Peroxisome Proliferator-activated Receptor Gamma by Apoptotic Cells Prevents Lipopolysaccharide-induced NCoR Removal From KappaB Binding Sites Mediating Transrepression of Proinf…
[cited by applicant]
Johnson, Barbara J, et al., Single-cell Perforin and Granzyme Expression Reveals the Anatomical Localization of Effector CD8+ T Cells in Influenza Virus-infected Mice. Proceedings of the National Academy of Sciences of …
[cited by applicant]
Johnson, Kenneth, et al., Discovery of Naturally Processed and HLA-Presented Class I Peptides from Vaccinia Virus Infection using Mass Spectrometry for Vaccine Development. Vaccine 28(1):38-47 (2009).
[cited by applicant]
Jones, Peter A, et al., The Epigenomics of Cancer. Cell 128(4):683-692 (2007).
[cited by applicant]
Jones, Peter A. Functions of DNA Methylation: Islands, Start Sites, Gene Bodies and Beyond. Nature Reviews Genetics 13(7):484-492 (2012).
[cited by applicant]
Jones, Philip, et al., InterProScan 5: Genome-Scale Protein Function Classification. Bioinformatics 30(9):1236-1240 (2014).
[cited by applicant]
Kalaora, Shelly, et al., Use of HLA Peptidomics and Whole Exome Sequencing to Identify Human Immunogenic Neo-Antigens. Oncotarget 7(5):5110-5117 (2016).
[cited by applicant]
Kandoth, Cyriac, et al., Mutational Landscape and Significance Across 12 Major Cancer Types. Nature 502(7471):333-339 (2013).
[cited by applicant]
Kannan, S. et al., Vaccination Strategies in Follicular Lymphoma. Current Hematologic Malignancy Reports 4(4):189-195 (2009).
[cited by applicant]
Karnani, Neerja, et al., Pan-S Replication Patterns and Chromosomal Domains Defined by Genome-Tiling Arrays of ENCODE Genomic Areas. Genome Research 17(6):865-876 (2007).
[cited by applicant]
Karolchik, Donna, et al., The UCSC Table Browser Data Retrieval Tool. Nucleic Acids Research 32:D493-D496 (2004).
[cited by applicant]
Kawai, Taro, et al., TLR Signaling. Seminars in Immunology 19(1):24-32 (2007).
[cited by applicant]
Keskin, Derin B, et al., Neoantigen Vaccine Generates Intratumoral T Cell Responses in Phase Ib Glioblastoma Trial. Nature 565(7738):234-239 (2019).
[cited by applicant]
Khong, Hung T, et al., Natural Selection of Tumor Variants in the Generation of “tumor escape” Phenotypes. Nature Immunology 3(11):999-1005 (2002).
[cited by applicant]
Kim, Daehwan et al. TopHat2: Accurate Alignment of Transcriptomes in the Presence of Insertions, Deletions and Gene Fusions. Genome Biology 14:R36, 1-13 (2013).
[cited by applicant]
Kim, Eun Ju, et al., mTOR Inhibitors Radiosensitize PTEN-Deficient Non-Small-Cell Lung Cancer Cells Harboring an EGFR Activating Mutation by Inducing Autophagy. Journal of Cellular Biochemistry 114(6):1248-1256 (2013).
[cited by applicant]
Kim, Jonghwan, et al., A Myc Network Accounts for Similarities Between Embryonic Stem and Cancer Cell Transcription Programs. Cell 143(2):313-324 (2010).
[cited by applicant]
Kim, Yohan, et al., Positional Bias of MHC Class I Restricted T-Cell Epitopes in Viral Antigens Is Likely due to a Bias in Conservation. PLoS Computational Biology 9(1):e1002884,8 Pages (2013).
[cited by applicant]
Kirkwood, John M, et al., High- and Low-Dose Interferon Alpha-2b in High-risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190. Journal of Clinical Oncology 18(12):2444-2458 (2000).
[cited by applicant]
Kirkwood, John M, et al., Interferon alfa-2b Adjuvant Therapy of High-risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology 14(1):7-17 (1996).
[cited by applicant]
Klebanoff, Christopher A, et al., Therapeutic Cancer Vaccines: are we there yet?. Immunological Reviews 239(1):27-44 (2011).
[cited by applicant]
Klein, Allon M, et al., Droplet Barcoding for Single-cell Transcriptomics Applied to Embryonic Stem Cells. Cell 161(5):1187-1201 (2015).
[cited by applicant]
Kloor, Matthias, et al., Immune Evasion of Microsatellite Unstable Colorectal Cancers. International Journal of Cancer 127(5):1001-1010 (2010).
[cited by applicant]
Klug, Felix, et al., Characterization of MHC Ligands for Peptide Based Tumor Vaccination. Current Pharmaceutical Design 15(28):3221-3236 (2009).
[cited by applicant]
Koch, Hauke., Combining Morphology and DNA Barcoding Resolves the Taxonomy of Western Malagasy Liotrigona Moure, 1961. African Invertebrates 51(2):413-421 (2010).
[cited by applicant]
Kreso, Antonija, et al., Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer. Science 339(6119):543-548 (2013).
[cited by applicant]
Kress, W. John, et al., DNA Barcodes: Genes, Genomics, and Bioinformatics. Proceedings of the National Academy of Sciences of the United States of America 105(8):2761-2762 (2008).
[cited by applicant]
Kress, W. John, et al., Use of DNA Barcodes to Identify Flowering Plants. Proceedings of the National Academy of Sciences of the United States of America 102(23):8369-8374 (2005).
[cited by applicant]
Kulis, Marta, et al., Epigenomic Analysis Detects Widespread Gene-Body DNA Hypomethylation in Chronic Lymphocytic Leukemia. Nature Genetics 44(11):1236-1242 (2012).
[cited by applicant]
Lahaye, Renaud, et al., DNA Barcoding the Floras of Biodiversity Hotspots. Proceedings of the National Academy of Sciences of the United States of America 105(8):2923-2928 (2008).
[cited by applicant]
Landan, Gilad, et al., Epigenetic Polymorphism and the Stochastic Formation of Differentially Methylated Regions in Normal and Cancerous Tissues. Nature Genetics 44(11):1207-1214 (2012).
[cited by applicant]
Landau, Dan A, et al., Clonal Evolution in Hematological Malignancies and Therapeutic Implications. Leukemia 28(1):34-43 (2014).
[cited by applicant]
Leffers, Ninke, et al., Immunization with a P53 Synthetic Long Peptide Vaccine Induces P53-Specific Immune Responses in Ovarian Cancer Patients, a Phase II Trial. International Journal of Cancer 125(9):2104-2113 (2009).
[cited by applicant]
Leffers, Ninke, et al., Long-term Clinical and Immunological Effects of p53-SLP® Vaccine in Patients with Ovarian Cancer. International Journal of Cancer 130(1):105-112 (2012).
[cited by applicant]
Lemay, Serge, et al., Dok-3, A Novel Adapter Molecule Involved in the Negative Regulation of Immunoreceptor Signaling. Molecular and Cellular Biology 20:2743-2754 (2000).
[cited by applicant]
Lewintre, Eloisa, et al., Analysis of Chronic Lymphotic Leukemia Transcriptomic Profile: Differences Between Molecular Subgroups. Leukemia & Lymphoma 50:68-79 (2009).
[cited by applicant]
Li, Bo, et al., RSEM: Accurate Transcript Quantification from RNA-Seq Data With or Without a Reference Genome. BMC Bioinformatics 12:323, 1-16 (2011).
[cited by applicant]
Li, Heng, et al., Fast and Accurate Long-Read Alignment with Burrows-Wheeler Transform. Bioinformatics 26(5):589-595 (2010).
[cited by applicant]
Li, Heng, et al., Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform. Bioinformatics 25(14):1754-1760 (2009).
[cited by applicant]
Li, Heng. et al. Mapping Short DNA Sequencing Reads and Calling Variants Using Mapping Quality Scores. Genome Research 18(11):1851-1858 (2008).
[cited by applicant]
Li, Meng, et al., Inactivating Mutations of the Chromatin Remodeling Gene ARID2 in Hepatocellular Carcinoma. Nature Genetics 43:828-829 (2011).
[cited by applicant]
Liggins, Amanda, et al., MORC4, A Novel Member of the MORC Family, is Highly Expressed in a Subset of Diffuse Large B-Cell Lymphomas. British Journal of Haematology 138:479-486 (2007).
[cited by applicant]
Lim, Elgene, et al., Transcriptome Analyses of Mouse and Human Mammary Cell Subpopulations Reveal Multiple Conserved Genes and Pathways. Breast Cancer Research 12:R21, 1-14 (2010).
[cited by applicant]
Lin, Katherine, et al., Relevance of the Immunoglobulin VH Somatic Mutation Status in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Related Chemoimmunother…
[cited by applicant]
Linardou, Helena, et al., Assessment of Somatic k-RAS Mutations as a Mechanism Associated with Resistance to EGFR-targeted Agents: A Systematic Review and Meta-Analysis of Studies in Advanced Non-Small-Cell Lung Cancer …
[cited by applicant]
Linardou, Helena, et al., Somatic EGFR Mutations and Efficacy of Tyrosine Kinase Inhibitors in NSCLC. Nature Reviews Clinical Oncology 6(6):352-366 (2009).
[cited by applicant]
Link et al., Electric control of droplets in microfluidic devices, Angew Chem Int Ed Engl, 45(16):2556-2560 (2006).
[cited by applicant]
Liu, Su-Yang, et al., Systematic Identification of Type I and Type II Interferon-Induced Antiviral Factors. Proceedings of the National Academy of Sciences of the United States of America 109(11):4239-4244 (2012).
[cited by applicant]
Livak, Kenneth J, et al., Methods for qPCR Gene Expression Profiling Applied to 1440 Lymphoblastoid Single Cells. Methods 59(1):71-79 (2013).
[cited by applicant]
Llobet, D, et al., CK2 Controls Trail and Fas Sensitivity by Regulating FLIP Levels in Endometrial Carcinoma Cells. Oncogene 27:2513-2524 (2008).
[cited by applicant]
Lohr, Jens, et al., Discovery and Prioritization of Somatic Mutations in Diffuse Large B-cell Lymphoma (DLBCL) by Whole-Exome Sequencing. Proceedings of the National Academy of Sciences of the United States of America 1…
[cited by applicant]
Lorente, Elena, et al., Diversity of Natural Self-Derived Ligands Presented by Different HLA Class I Molecules in Transporter Antigen Processing-deficient Cells. PLoS One 8:10 pages (2013).
[cited by applicant]
Lozzio et al.: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45(3):321-334 (1975).
[cited by applicant]
Lu, Yong-Chen, et al., Mutated 1PPP1R3B is Recognized by T Cells Used to Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. Journal of Immunology 190(12):6034-6042 (2013).
[cited by applicant]
Lucas, S, et al., About Human Tumor Antigens to be used in Immunotherapy. Seminars in Immunology 20(5):301-307 (2008).
[cited by applicant]
Lund, Jennifer, et al., Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells. Science 320(5880):1220-1224 (2008).
[cited by applicant]
Luo, Heng, et al., Machine Learning Methods for Predicting HLA-Peptide Binding Activity. Bioinformatics and Biology Insights 9(S3):21-29 (2015).
[cited by applicant]
Ma, Bin., Novor: Real-Time Peptide De Novo Sequencing Software. Journal of the American Society for Mass Spectrometry 26:1885-1894 (2015).
[cited by applicant]
Maegawa, Shinji, et al., Age-Related Epigenetic Drift in the Pathogenesis of MDS and AML. Genome Research 24:580-591 (2014).
[cited by applicant]
Mair, Barbara, et al., Gain- and Loss-of-function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. Public Library of Science Genetics 12(9):e1006279, 1-26 (2016).
[cited by applicant]
Marshall, K W, et al., Role of the Polymorphic Residues in HLA-DR Molecules in Allele-specific Binding of Peptide Ligands. Journal of Immunology 152(10):4946-4957 (1994).
[cited by applicant]
Matsumura, Noriomi. et al. Immunostimulatory effect of FMS-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment. Oncology Report…
[cited by applicant]
Mayer, Jens, et al., A Revised Nomenclature for Transcribed Human Endogenous Retroviral Loci. Mobile DNA 2:7, 8 Pages (2011).
[cited by applicant]
McCleskey et al., GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse. Am J Clin Pathol. Nov. 2015;144(5):756-63. doi: 10.1309/AJCP5MMR1FJVVTPK. PMID: 26486740.
[cited by applicant]
McMurtrey, Curtis, et al., Toxoplasma Gondii Peptide Ligands Open the Gate of the HLA Class I Binding Groove. eLife 5:e12556,19 Pages (2016).
[cited by applicant]
Medema, Jan Paul, et al., Immune Escape of Tumors in Vivo by Expression of Cellular FLICE-Inhibitory Protein. The Journal of Experimental Medicine 190:1033-1038 (1999).
[cited by applicant]
Meissnar, Alexander, et al., Genome-Scale DNA Methylation Maps of Pluripotent and Differentiated Cells. Nature 454:766-770 (2008).
[cited by applicant]
Menkle, Aswin L, et al., Genetic Interactions Between the Wilms' Tumor 1 Gene and the P53 Gene. Cancer Research 62(22):6615-6620 (2002).
[cited by applicant]
Mermel, Craig H. et al. GISTIC2. 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome biology 12:R41, 1-14 (2011).
[cited by applicant]
Messmer, Bradley T, et al., In Vivo Measurements Document the Dynamic Cellular Kinetics of Chronic Lymphocytic Leukemia B Cells. The Journal of Clinical Investigation 115(3):755-764 (2005).
[cited by applicant]
Milner, Elena, et al., The Effect of Proteasome Inhibition on the Generation of the Human Leukocyte Antigen (HLA) Peptidome. Molecular & Cellular Proteomics 12:1853-1864 (2013).
[cited by applicant]
Milner, Elena, et al., The Turnover Kinetics of Major Histocompatibility Complex Peptides of Human Cancer Cells. Molecular & Cellular Proteomics 5:357-365 (2006).
[cited by applicant]
Missale, Gabriele, et al., HLA-A31- and HLA-Aw68-restricted Cytotoxic T Cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope During Acute Viral Hepatitis. The Journal of Experimental Medicine 177(3):751-762…
[cited by applicant]
Mocellin, Simone, et al., Interferon Alpha Adjuvant Therapy in Patients With High-risk Melanoma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute 102(7):493-501 (2010).
[cited by applicant]
Morison, Ian M, et al., A Census of Mammalian Imprinting. Trends in Genetics 21(8):457-465 (2005).
[cited by applicant]
Morozov, Vladimir A, et al., The Transmembrane Protein of the Human Endogenous Retrovirus--K (HERV-K) Modulates Cytokine Release and Gene Expression. PLoS One 8(8):e70399,9 Pages (2013).
[cited by applicant]
Morton, Donald L, et al., Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes. Annals of Sur…
[cited by applicant]
Mosmann, T.R, et al., TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties. Annual Review of Immunology 7:145-173 (1989).
[cited by applicant]
Muller et al., Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 58(12):3873-83 (2008).
[cited by applicant]
Muntel, Jan, et al., Abundance-based Classifier for the Prediction of Mass Spectrometric Peptide Detectability Upon Enrichment (PPA). Molecular & Cellular Proteomics 14:430-440 (2015).
[cited by applicant]
Ng, Julio, et al., Dereplication and De Novo Sequencing of Nonribosomal Peptides. Nature Methods 6:596--599 (2009).
[cited by applicant]
Nielsen, Morten, et al., NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence. PLoS One 2:e796, 10 Pages (2007).
[cited by applicant]
Nielsen, Morten, et al., NetMHCpan-3.0; Improved Prediction of Binding to MHC Class I Molecules Integrating Information from Multiple Receptor and Peptide Length Datasets. Genome Medicine 8:33,9 Pages (2016).
[cited by applicant]
Nielsen, Morten, et al., The Role of the Proteasome in Generating Cytotoxic T-cell Epitopes: Insights Obtained from Improved Predictions of Proteasomal Cleavage. Immunogenetics 57:33-41 (2005).
[cited by applicant]
Novershtern, Noa, et al., Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis. Cell 144(2):296-309 (2011).
[cited by applicant]
Ohnishi, Kotaro, et al., Premature Termination of Reprogramming in Vivo Leads to Cancer Development Through Altered Epigenetic Regulation. Cell 156(4):663-677 (2014).
[cited by applicant]
Okada, Hideho. et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid…
[cited by applicant]
Oshiumi, Hiroyuki, et al., DEAD/H BOX 3 (DDX3) Helicase Binds the RIG-I Adaptor IPS-1 to Up-regulate IFN-beta-inducing Potential. European Journal of Immunology 40(4):940-948 (2010).
[cited by applicant]
Ott, Patrick, et al., CTLA-4 and PD-1/PD-L1 blockade: New Immunotherapeutic Modalities With Durable Clinical Benefit in Melanoma Patients. Clinical Cancer Research 19(19):5300-5309 (2013).
[cited by applicant]
Padgett, K A, et al., Creating Seamless Junctions Independent of Restriction Sites in Pcr Cloning. Gene 168(1):31-35 (1996).
[cited by applicant]
Pagès, Franck, et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. New England Journal of Medicine 353(25):2654-2666 (2005).
[cited by applicant]
Pan et al.: Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine. Oncotarget. 8(47):82689-82699 (2017).
[cited by applicant]
PCT/US2011/036665 International Preliminary Report on Patentability dated Nov. 20, 2012.
[cited by applicant]
PCT/US2014/033185 International Preliminary Report on Patentability dated Oct. 22, 2015.
[cited by applicant]
PCT/US2014/067146 International Preliminary Report on Patentability dated May 31, 2016.
[cited by applicant]
PCT/US2014/068746 International Preliminary Report on Patentability dated Jun. 7, 2016.
[cited by applicant]
PCT/US2014/068893 International Preliminary Report on Patentability dated Jun. 7, 2016.
[cited by applicant]
PCT/US2014/071707 International Preliminary Report on Patentability dated Jun. 21, 2016.
[cited by applicant]
PCT/US2021/045800 International Search Report and Written Opinion dated Dec. 22, 2021.
[cited by applicant]
PCT/US2022/078161 International Search Report and Written Opinion dated Feb. 16, 2023.
[cited by applicant]
PCT/US2023/083256 International Search Report and Written Opinion dated Mar. 26, 2024.
[cited by applicant]
Pei, Lirong, et al., Genome-wide DNA Methylation Analysis Reveals Novel Epigenetic Changes in Chronic Lymphocytic Leukemia. Epigenetics 7(6):567-578 (2012).
[cited by applicant]
Peng, Qisheng, et al., DOK3 Negatively Regulates LPS Responses and Endotoxin Tolerance. Public Library of Science one 7(6):e39967, 11 Pages (2012).
[cited by applicant]
Perez, C A, et al., p63 Consensus DNA-binding Site: Identification, Analysis and Application Into a p63MH Algorithm. Oncogene 26(52):7363-7370 (2007).
[cited by applicant]
Pieters, Jean, et al., On Guard: Coronin Proteins in Innate and Adaptive Immunity. Nature Reviews Immunology 13(7):510-518 (2013).
[cited by applicant]
Pirard, Delphine, et al., Interferon Alpha as Adjuvant Postsurgical Treatment of Melanoma: A Meta-analysis. Dermatology 208(1):43-48 (2004).
[cited by applicant]
Poncette, Lucia. et al. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression. J Clin Invest 129(1):324-335. (2019) Published online Dec. 10, 2018.
[cited by applicant]
Powell, Maria L C, et al., NCoR1 Mediates Papillomavirus E8;E2CTranscriptional Repression. Journal of Virology 84(9):4451-4460 (2010).
[cited by applicant]
Pujadas, Elisabet, et al., Regulated Noise in the Epigenetic Landscape of Development and Disease. Cell 148(6):1123-1131 (2012).
[cited by applicant]
Qin, Dong, et al., Soft Lithography for Micro- and Nanoscale Patterning. Nature protocols 5(3):491-502 (2010).
[cited by applicant]
Quesada, Victor, et al., Exome Sequencing Identifies Recurrent Mutations of the Splicing Factor SF3B1 Gene in Chronic Lymphocytic Leukemia. Nature genetics 44(1):47-52 (2011).
[cited by applicant]
Quezada, Sergio, et al., CTLA4 Blockade and GM-CSF Combination Immunotherapy Alters the Intratumor Balance of Effector and Regulatory T Cells. Journal of Clinical Investigation 116(7):1935-1945 (2006).
[cited by applicant]
Ramsköld, Daniel, et al., Full-length mRNA-Seq From Single-cell Levels of RNA and Individual Circulating Tumor Cells. Nature Biotechnology 30(8):777-782 (2012).
[cited by applicant]
Rassenti, Laura, et al., Relative Value of ZAP-70, CD38, and Immunoglobulin Mutation Status in Predicting Aggressive Disease in Chronic Lymphocytic Leukemia. Blood 112(5):1923-1930 (2008).
[cited by applicant]
Raval, Aparna, et al., Downregulation of Death-associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia. Cell 129(5):879-890 (2007).
[cited by applicant]
Ravi, Rajani, et al., Sensitization of Tumor Cells to Apo2 Ligand/TRAIL-Induced Apoptosis by Inhibition of Casein Kinase II. Cancer Research 62(15):4180-4185 (2002).
[cited by applicant]
Richter, Wolfgang F, et al., Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration. American Association of Pharmaceutical Scientists Journal 14(3):559-570 (2012).
[cited by applicant]
Rini, Brian I, et al., Biology and Treatment of Advanced Renal Cell Carcinoma: a Global Perspective. Seminars in oncology 40(4):419-420 (2013).
[cited by applicant]
Robbins, Paul F, et al., Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T Cells. Nature Medicine 19(6):747-752 (2013).
[cited by applicant]
Robinson, James T, et al., Integrative Genomics Viewer. Nature Biotechnology 29(1):24-26 (2011).
[cited by applicant]
Robinson, Mark D, et al., edgeR: a Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data. Bioinformatics 26(1):139-140 (2010).
[cited by applicant]
Robinson, R A, et al., A Phase I-II Trial of Multiple-dose Polyriboinosic-polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal of the National Cancer Institute 57(3):599-602 (1976).
[cited by applicant]
Rosenberg, Steven A., Raising the Bar: the Curative Potential of Human Cancer Immunotherapy. Science Translational Medicine 4(127):127ps8, 5 pages (2012).
[cited by applicant]
Rossi, Davide, et al., Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. Blood 121(8):1403-1412 (2013).
[cited by applicant]
Rubin, Alan F, et al., Mutation Patterns in Cancer Genomes. Proceedings of the National Academy of Sciences of the United States of America 106(51):21766-21770 (2009).
[cited by applicant]
Rubio-Moscardo, Fanny, et al., Characterization of 8p21.3 Chromosomal Deletions in B-cell Lymphoma: TRAIL-R1 and TRAIL-R2 as Candidate Dosage-dependent Tumor Suppressor Genes. Blood 106(9):3214-3222 (2005).
[cited by applicant]
Rutledge, Caleb W, et al., Tumor-infiltrating Lymphocytes in Glioblastoma Are Associated With Specific Genomic Alterations and Related to Transcriptional Class. Clinical Cancer Research 19(18):4951-4960 (2013).
[cited by applicant]
Saint-Jean, Melanie. et al. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. J Immunol Res 2018:3530148, 1-10 (2018).
[cited by applicant]
Salem, Mohamed L, et al., Defining the Antigen-specific T-cell Response to Vaccination and Poly(I:C)/TLR3 Signaling: Evidence of Enhanced Primary and Memory CD8 T-cell Responses and Antitumor Immunity. Journal of Immuno…
[cited by applicant]
Samuels, Yardena, et al., Oncogenic PI3K and its Role in Cancer. Current Opinion in Oncology 18(1):77-82 (2006).
[cited by applicant]
Sato, Norihiro, et al., Discovery of Novel Targets for Aberrant Methylation in Pancreatic Carcinoma Using High-throughput Microarrays. Cancer Research 63(13):3735-3742 (2003).
[cited by applicant]
Saturno, Grazia, et al., Combining Trail With PI3 Kinase or HSP90 Inhibitors Enhances Apoptosis in Colorectal Cancer Cells via Suppression of Survival Signaling. Oncotarget 4(8):1185-1198 (2013).
[cited by applicant]
Schmitt, Katja, et al., Transcriptional Profiling of Human Endogenous Retrovirus Group HERV-K(HML-2) Loci in Melanoma. Genome Biology and Evolution 5(2):307-328 (2013).
[cited by applicant]
Schreiber, Robert D, et al., Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science 331(6024):1565-1570 (2011).
[cited by applicant]
Schumacher, K, et al., Prognostic Significance of Activated CD8(+) T Cell Infiltrations Within Esophageal Carcinomas. Cancer research 61(10):3932-3936 (2001).
[cited by applicant]
Schuster, Stephen J, et al., Vaccination With Patient-specific Tumor-derived Antigen in First Remission Improves Disease-free Survival in Follicular Lymphoma. Journal of Clinical Oncology 29(20):2787-2794 (2011).
[cited by applicant]
Secchiero, Paola, et al., Aberrant Expression of TRAIL in B Chronic Lymphocytic Leukemia (B-CLL) Cells. Journal of Cellular Physiology 205(2):246-252 (2005).
[cited by applicant]
Selezneva et al.: Complex Approach to the Study of Pharmacological Agents In Vitro, Ex Vivo, In Vivo. International Research Journal. 6(37):1-13 (2015).
[cited by applicant]
Sensi, Marialuisa, et al., Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-mediated Patient-specific Immunotherapy. Clinical Cancer Research 12(17):5023-5032 (20…
[cited by applicant]
Serafini, Paolo. et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203(12):2691-2702 (2006).
[cited by applicant]
Shah, Neil P, et al., Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia. Cancer cell 2(2)…
[cited by applicant]
Shannon, C E, et al., A Mathematical Theory of Communication. The Bell System Technical Journal 27(3):379-423 (1948).
[cited by applicant]
Shao, Haipeng, et al., Clonally Related Histiocytic/dendritic Cell Sarcoma and Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma: a Study of Seven Cases. Modern Pathology 24(11):1421-1432 (2011).
[cited by applicant]
Shendure, Jay, and Hanlee Ji. Next-generation DNA sequencing. Nature biotechnology 26(10):1135-1145 (2008).
[cited by applicant]
Sidney, John, et al., HLA Class I Supertypes: a Revised and Updated Classification. BioMed Central Immunology 9:1, 15 Pages (2008).
[cited by applicant]
Sidney, John. et al. Several HLA Alleles Share Overlapping Peptide Specificities. The Journal of Immunology 154(1):247-259 (1995).
[cited by applicant]
Siegel, Rebecca, et al., Cancer Statistics, 2013. Cancer Journal for Clinicians 63(1):11-30 (2013).
[cited by applicant]
Simmons, Andrew D, et al., Local Secretion of Anti-CTLA-4 Enhances the Therapeutic Efficacy of a Cancer Immunotherapy With Reduced Evidence of Systemic Autoimmunity. Cancer Immunology and Immunotherapy 57(8):1263-1270 (…
[cited by applicant]
Simpson, Andrew J G, et al., Cancer/testis Antigens, Gametogenesis and Cancer. Nature Reviews Cancer 5(8):615-625 (2005).
[cited by applicant]
Simpson, Tyler R, et al., Fc-dependent Depletion of Tumor-infiltrating Regulatory T Cells Co-defines the Efficacy of Anti-CTLA-4 Therapy Against Melanoma. Journal of Experimental Medicine 210(9):1695-1710 (2013).
[cited by applicant]
Slingluff, Craig L, et al., Randomized Multicenter Trial of the Effects of Melanoma-associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine. Journal of Clinical Oncology …
[cited by applicant]
Soares, Helena, et al., A Subset of Dendritic Cells Induces Cd4+ T Cells to Produce IFN-gamma by an IL-12-independent but CD70-dependent Mechanism in Vivo. The Journal of Experimental Medicine 2215(11):1095-1106 (2007).
[cited by applicant]
Soininen, Eeva M, et al., Analysing Diet of Small Herbivores: the Efficiency of DNA Barcoding Coupled With High-throughput Pyrosequencing for Deciphering the Composition of Complex Plant Mixtures. Frontiers in Zoology 6…
[cited by applicant]
Song, Jae J, et al., c-Cbl Acts as a Mediator of Src-Induced Activation of the PI3K-Akt Signal Transduction Pathway During TRAIL Treatment. Cellular Signalling 22(3):377-385 (2010).
[cited by applicant]
Sosman, Jeffrey A, et al., A Phase 2 Trial of Complete Resection for Stage IV Melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 117(20):4740-4746 (2011).
[cited by applicant]
Speetjens, Frank M, et al., Induction of P53-specific Immunity by a P53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer. Clinical Cancer Research : an Official Journal of the American…
[cited by applicant]
Spencer, Sabrina L, et al., Non-genetic Origins of Cell-to-cell Variability in Trail-Induced Apoptosis. Nature 459:428-432 (2009).
[cited by applicant]
Spranger, Stefani. et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5(200):200ra116, 1-10 (2013).
[cited by applicant]
Srivastava, Nisheeth, et al., Modeling the Repertoire of True Tumor-specific Mhc I Epitopes in a Human Tumor. PloS One 4(7):e6094, 5pages (2009).
[cited by applicant]
Srivastava, Pramod K., Therapeutic Cancer Vaccines, Current Opinion in Immunology 18:201-205 (2006).
[cited by applicant]
Stransky, Nicolas. et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. Science 333(6046):1157-1160 (2011).
[cited by applicant]
Stranzl, Thomas, et al., NetCTLpan: Pan-Specific MHC Class I Pathway Epitope Predictions. Immunogenetics 62(6):357-368 (2010).
[cited by applicant]
Su, Zhenqiang, et al., Next-generation Sequencing and its Applications in Molecular Diagnostics. Expert Review of Molecular Diagnostics 11(3):333-343 (2011).
[cited by applicant]
Suzuki, kichiya, et al., A Novel Glycosylphosphatidyl Inositol-anchored Protein on Human Leukocytes: a Possible Role for Regulation of Neutrophil Adherence and Migration. Journal of Immunology 162(7):4277-4284 (1999).
[cited by applicant]
Sykulev, Yuri, et al., Evidence That a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response. Immunity 4:565-571 (1996).
[cited by applicant]
Takaku, Motoki, et al., GATA3 in Breast Cancer: Tumor Suppressor or Oncogene?. Gene Expression 16(4):163-168 (2015).
[cited by applicant]
Takaku, Motoki, et al., GATA3 Zinc Finger 2 Mutations Reprogram the Breast Cancer Transcriptional Network. Nature Communications 9(1):1059, 14 Pages (2018).
[cited by applicant]
Tan, et al., “Induction of CTLs by DCs pulsed with K-ras mutant peptide on the surface of nanoparticles in the treatment of pancreatic cancer” Oncology Reports (2011) 26: 215-221.
[cited by applicant]
Tang, Ka-Wei, et al., The Landscape of Viral Expression and Host Gene Fusion and Adaptation in Human Cancer. Nature Communications 4:2513, 9pages (2013).
[cited by applicant]
Tang, Shaojun, et al., NeoantigenR: An Annotation Based Pipeline for Tumor Neoantigen Identification from Sequencing Data. BioRxiv preprint :19pages (2017).
[cited by applicant]
Ten Bosch, John R, et al., Keeping Up With the Next Generation: Massively Parallel Sequencing in Clinical Diagnostics. The Journal of Molecular Diagnostics 10(6):484-492 (2008).
[cited by applicant]
Testori, Alessandro, et al., Phase III Comparison of Vitespen, an Autologous Tumor-derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: the C-100-21 Study …
[cited by applicant]
Textor, Sonja, et al., Human NK Cells Are Alerted to Induction of P53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2. Cancer Research 71:5998-6009 (2011).
[cited by applicant]
The Cancer Genome Atlas Network, Comprehensive Molecular Portraits of Human Breast Tumours. Nature 490(7418):61-70 (2012).
[cited by applicant]
Thillier, Yann. et al. Synthesis of 5′ cap-0 and cap-1 RNAs using solid-phase chemistry coupled with enzymatic methylation by human (guanine-N
[cited by applicant]
Timp, Winston, et al., Cancer as a Dysregulated Epigenome Allowing Cellular Growth Advantage at the Expense of the Host. Nature Reviews.Cancer 13:497-510 (2013).
[cited by applicant]
Tough, David F, et al., Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo. Science 272(5270):1947-1950 (1996).
[cited by applicant]
Tran, Eric et al., Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science 344(6184):641-645 (2014).
[cited by applicant]
Tran, et al., “T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer” N Engl J Med Dec. 8, 2016; 375(23): 2255-2262.
[cited by applicant]
Trolle, Thomas, et al., Automated Benchmarking of Peptide-MHC Class I Binding Predictions. Bioinformatics 31(13):2174-2181 (2015).
[cited by applicant]
Trumpfheller, Christine, et al., Intensified and Protective CD4+ T Cell Immunity in Mice With Anti-dendritic Cell HIV gag Fusion Antibody Vaccine. The Journal of Experimental Medicine 203(3):607-617 (2006).
[cited by applicant]
Trumpfheller, Christine, et al., The Microbial Mimic Poly IC Induces Durable and Protective CD4+ T Cell Immunity Together With a Dendritic Cell Targeted Vaccine. Proceedings of the National Academy of Sciences of the Un…
[cited by applicant]
Tucker, Tracy. et al. Massively Parallel Sequencing:The Next Big Thing in Genetic Medicine. American Journal of Human Genetics 85(2):142-154 (2009).
[cited by applicant]
Turchaninova, Maria A, et al., Pairing of T-cell Receptor Chains via Emulsion PCR. European Journal of Immunology 43:2507-2515 (2013).
[cited by applicant]
Uderhardt, Stefan, et al., 12/15-Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains Immunologic Tolerance. Immunity 36(5):834-846 (2012).
[cited by applicant]
U.S. Appl. No. 13/108,610 Office Action dated Aug. 15, 2013.
[cited by applicant]
U.S. Appl. No. 13/108,610 Office Action dated Dec. 3, 2014.
[cited by applicant]
U.S. Appl. No. 14/794,449 Office Action dated Dec. 29, 2016.
[cited by applicant]
U.S. Appl. No. 14/794,449 Office Action dated Jul. 24, 2018.
[cited by applicant]
U.S. Appl. No. 14/877,125 Office Action dated Mar. 27, 2017.
[cited by applicant]
U.S. Appl. No. 14/877,125Office Action dated Nov. 2, 2018.
[cited by applicant]
U.S. Appl. No. 15/038,504 Office Action dated Sep. 6, 2017.
[cited by applicant]
U.S. Appl. No. 15/102,129 Office Action dated Dec. 17, 2018.
[cited by applicant]
U.S. Appl. No. 15/102,129 Office Action dated Jul. 28, 2017.
[cited by applicant]
U.S. Appl. No. 15/102,129 Office Action dated Mar. 7, 2018.
[cited by applicant]
U.S. Appl. No. 15/105,961 Office Action dated Jan. 8, 2019.
[cited by applicant]
U.S. Appl. No. 15/105,961 Office Action dated Nov. 20, 2017.
[cited by applicant]
U.S. Appl. No. 15/187,174 Office Action dated Dec. 5, 2016.
[cited by applicant]